reports
- Hilde Van Boxstael
- Mathijs Geerts Danau
- Wim Lewi
- Mathijs Geerts Danau
Sequana Medical New DSR patent improves value of program
Sequana announces granting of a key additional methods and formulation patent for DSR. This patent increases durability and expands protection of Sequana's DSR IP, thereby improving its value. We note that the patent provides additional time for Sequana to secure dedicated financing to advance DSR toward the randomized controlled portion of the MOJAVE clinical study. We reiterate our BUY rating.
- Wim Hoste
Umicore EU looks set to abandon combustion engine ban in 2035
Based on various press articles, it seems increasingly likely that the European Union is to abandon the earlier agreed ban on new combustion engine-based passenger cars by 2035, whilst new legislation would still require a significant reduction of tailpipe emissions. Any loosening of legislation would probably be good news for Umicore's Catalysts business, with European ICE Light duty Automotive Catalysts' revenue representing c. 28% of total ICE light duty Automotive Catalysts' revenue. We awai...
- Dominic Rose
- Naresh Chouhan
Thematic - 2026 Outlook - "5 More Years" (55pgs)
For access to the full note, please contact Naresh Chouhan ( ) With EU Pharma (ex-Novo) now having reached decade high valuations vs EuroStoxx600, we believe the sector has broken out & the sustainability of the growth profile will now generate continued strong performance. Consensus 5yr sales & EPS CAGR’s stand at 4% & 7% for 15x 2026 PE. We show there is upside to this from underestimated pipelines where cons. rarely fully models “monster” drugs & from M&A which we expect to be strong at JPM ...
- Guy Sips
- Hilde Van Boxstael
- Jacob Mekhael
- Kristof Samoy
- Livio Luyten
- Mathijs Geerts Danau
- Michiel Declercq
- Wim Hoste
- Wim Lewi
- Hilde Van Boxstael
- Mathijs Geerts Danau
- Michiel Declercq
- Thomas Couvreur
- Wim Hoste
- Wim Lewi
- Mathijs Geerts Danau
UCB Detailed results from Fintepla in CDD strengthen epilepsy franchis...
UCB presented detailed results of the positive phase 3 GEMZ study with Fintepla in CDKL5 deficiency disorder (CDD). The drug showed an estimated 52.7% median reduction in countable motor seizure frequency (CMSF) compared with placebo during a 14 week titration and maintenance period and a favourable safety profile. We view this as highly encouraging in this refractory epilepsy population. Given the infantile onset of CDD, we will be curious to see as of which age, patients could be included in t...
- Ahmed Ben Salem
- Baptiste Salaville
- Oddo Sustainability Team
- Martial Descoutures
- Martial Descoutures
- Ahmed Ben Salem
- Baptiste Salaville
- Oddo Sustainability Team
- ING Helpdesk
- Hilde Van Boxstael
- Jacob Mekhael
- Wim Lewi
- Jacob Mekhael
UCB Announces another FY25 guidance upgrade
UCB announced an additional upgrade to its FY25 financial guidance, where it now expects revenue to exceed € 7.6b, representing +24% y/y (previously at least € 7b), and adj. EBITDA margin to be higher than 31% (previously at least 30%). This is the company's second guidance upgrade this year and shows that UCB's commercial momentum continues its upward trajectory supported by its 5 key growth drivers, including lead product Bimzelx which saw strong momentum in HS, as well as a favourable payer m...
- Mathijs Geerts Danau
Sequana Medical Announces first US sale of the alfapump
Sequana reported the first US commercial alfapump implant at Mount Sinai Hospital in New York. This important milestone shows the demand for the alfapump in the US. We adjust our TP from € 2.8 to € 2.7 to reflect the new share count and reiterate our BUY rating.
- Guy Sips
- Hilde Van Boxstael
- Jacob Mekhael
- Mathijs Geerts Danau
- Thibault Leneeuw
- Wim Lewi
- Guy Sips
- Jacob Mekhael
- Livio Luyten
- Wim Hoste
- Adrian Pehl
- Marc Lavaud
FII LISI SA
VOE VOESTALPINE AG
SDF K+S AG
INH INDUS HOLDING AG
PAL PALFINGER AG
SEM SEMPERIT HOLDING AG
ADN1 ADESSO AG
PAT PATRIZIA AG
SAX STROEER SE & CO. KGAA
POST OSTERREICHISCHE POST AG
TWEKA TKH GROUP N.V. CERT
CSM CORBION NV
FACC FACC AG
JUN3 JUNGHEINRICH AG PREF
JEN JENOPTIK AG
KTA KNAUS TABBERT
SFQ SAF-HOLLAND SE
VT5 VT5 ACQUISITION COMPANY AG
SPG SPRINGER NATURE AG & CO. KGAA
CAN CANAL+
- Adrian Pehl
- Marc Lavaud
FII LISI SA
VOE VOESTALPINE AG
SDF K+S AG
INH INDUS HOLDING AG
PAL PALFINGER AG
SEM SEMPERIT HOLDING AG
ADN1 ADESSO AG
PAT PATRIZIA AG
SAX STROEER SE & CO. KGAA
POST OSTERREICHISCHE POST AG
TWEKA TKH GROUP N.V. CERT
CSM CORBION NV
FACC FACC AG
JUN3 JUNGHEINRICH AG PREF
JEN JENOPTIK AG
KTA KNAUS TABBERT
SFQ SAF-HOLLAND SE
VT5 VT5 ACQUISITION COMPANY AG
SPG SPRINGER NATURE AG & CO. KGAA
CAN CANAL+
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.